Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

Abstract: The present invention provides an efficient process for the isolation of natural crystallized thymol product derived from crude natural Monarda citriodora (Jammu Monarda) oil useful for incorporation into foods and beverages in amounts due to strong antimicrobial, antibacterial, antioxidant properties as well as for use as a preservative. The recovery of crystallized thymol product obtained is more than 72% from Hexane-Jammu Monarda oil in a ratio 1:1 under specific conditions. A method for preparing natural thymol in crystal form involves providing crude Jammu Monarda oil in a Flask and gradually reducing the temperature of the flask containing Monarda oil: Hexane in a step-wise manner, thereby producing highly pure crystals (?95.5%) within 48 h. The methods disclosed herein are suitable for pharmaceutical GMP.

Abstract: Systems and methods for digital identity verification are disclosed. In one embodiment, in an information processing apparatus comprising at least one computer processor, a method for digital identify verification may include: (1) receiving, from a user electronic device or at a website, an image of an identity document for a user, the identity document comprising an image of the user; (2) processing the identity document with at least one business-specific rule; (3) extracting identity information from the identity document; (4) determining a match rate of the image of the user on the identity document to a captured image; (5) assigning a verification score to the user based on extracted identity information and the match rate; and (6) publishing the verification score to at least one system.

Abstract: Exemplary apparatus can be provided which can include a laser arrangement that is configured to provide a laser radiation, and including an optical cavity. The optical cavity can include a dispersive optical waveguide first arrangement having first and second sides, and which is configured to (i) receive at least one first electro-magnetic radiation at the first side so as to provide at least one second electro-magnetic radiation, and (ii) to receive at least one third electro-magnetic radiation at the second side so as to provide at least one fourth electro-magnetic radiation. The first and second sides are different from one another, and the second and third radiations are related to one another. The optical cavity can also include an active optical modulator second arrangement which can be configured to receive and modulate the fourth radiation so as to provide the first electro-magnetic radiation to the first arrangement.

Abstract: An apparatus can be provided which can include a laser arrangement which can be configured to provide a laser radiation, and can include an optical cavity. The optical cavity can include a dispersive optical first arrangement which can be configured to receive and disperse at least one first electro-magnetic radiation so as to provide at least one second electro-magnetic radiation. Such cavity can also include an active optical modulator second arrangement which can be configured to receive and modulate the at least one second radiation so as to provide at least one third electro-magnetic radiation. The optical cavity can further include a dispersive optical third arrangement which can be configured to receive and disperse at least one third electro-magnetic radiation so as to provide at least one fourth electro-magnetic radiation.

Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.

Abstract: Techniques for user-based service discovery in a network are described. In one embodiment, a method includes receiving, at a controller, a query to discover advertised services from a user device from a local area network. The method includes determining one or more advertised services in response to the query from the user device and determining a service discovery gateway agent for the local area network in communication with the user device. A query response that includes the one or more advertised services determined in response to the query is transmitted to the service discovery gateway agent. The service discovery gateway agent is configured to receive the query response and transmit the one or more advertised services to the user device via a Layer 2 unicast transmission.

Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

Abstract: The present invention relates to a superhydrophilic biodegradable cross linked foam membrane and a process for preparation of said foam membrane from a seaweed polysaccharides by blending with amino biopolymers/amino acids/proteins/amino compounds followed by crosslinking with a naturally occurring cross linker, genipin. The foam membrane can be used as a substitute for synthetic membrane for varied applications including membrane separation for oil-water emulsions, oil-water mixtures and other aqueous-organic mixtures under ambient conditions. These foam membranes can be recycled and reused more than three times without considerable decrease in flux rate and stability. The separation methodology of the mixtures using the foam membrane of the present invention is gravity-driven and therefore, simple and energy-efficient.

Abstract: System and method for improving recognition of characters. A system for improving recognition of characters is disclosed. The system comprises at least one processor (10), configured to receive an image (1004) of an article (102) comprising characters to be recognized. The system (100) displays characters as recognized on a display screen (1006). Further, the system (100) is configured to receive user feedback comprising correction of an error made by the system (100) in recognizing at least one character and provide a system feedback comprising display of images or textual descriptions of one or more variants (1012, 1014, 1016, 1018, 1020, 1022) of a character, which is incorrectly recognized by the system, which enables the natural person to adapt writing style to enable better quality inputs to the recognition module. The article (102) is a handwritten paper form (102), filled and captured by the natural person.

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

Abstract: An apparatus can be provided which can include a laser arrangement which can be configured to provide a laser radiation, and can include an optical cavity. The optical cavity can include a dispersive optical first arrangement which can be configured to receive and disperse at least one first electro-magnetic radiation so as to provide at least one second electro-magnetic radiation. Such cavity can also include an active optical modulator second arrangement which can be configured to receive and modulate the at least one second radiation so as to provide at least one third electro-magnetic radiation. The optical cavity can further include a dispersive optical third arrangement which can be configured to receive and disperse at least one third electro-magnetic radiation so as to provide at least one fourth electro-magnetic radiation.

Abstract: Techniques for user-based service discovery in a network are described. In one embodiment, a method includes receiving, at a controller, a query to discover advertised services from a user device from a local area network. The method includes determining one or more advertised services in response to the query from the user device and determining a service discovery gateway agent for the local area network in communication with the user device. A query response that includes the one or more advertised services determined in response to the query is transmitted to the service discovery gateway agent. The service discovery gateway agent is configured to receive the query response and transmit the one or more advertised services to the user device via a Layer 2 unicast transmission.

Abstract: Examples provide machine language (“ML”)-powered on-time delivery prediction generation for virtual orders obtained from an order management component (“OMC”). Predictions based on order factors deterministic to on-time delivery are output to the OMC. Predictions become increasingly accurate over time based on the accuracy of past delivery predictions and give the probabilistic chance of on-time delivery (the “order-score”) in real-time before an order for goods and/or services is dispatched. The OMC uses the order-score to react preemptively to mitigate delay factors on orders likely to arrive late, increasing the probability of on-time delivery. Customers are given confidence predicted arrival times are accurate enough for scheduling purposes. Providers more easily maintain and grow good reputations and revenue.

Abstract: Systems and methods of the present disclosure provide comprehensive risk assessment in a heterogeneous dynamic network. The framework enables ‘view’ and ‘analyses’ of complete architecture simultaneously in information view, deployment view, business view and security view. Fundamentally, data pertaining to information flow between a plurality of nodes within systems in a network is identified. One or more affected nodes or paths therebetween are identified and attack risk is computed. The graph based framework supports multiple threat models for threat evaluation. It also provides mitigation plans which will reflect reduced risk in the business view and incorporates attack tree simulations to evaluate dynamic behavior of a system under attack.

Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.

Abstract: A battery powered auxiliary HVAC system designed to heat and cool at least a sleeper compartment of a vehicle such as a truck with a management system for conserving battery power. The management system includes a processor connected to temperature sensors, motion sensors, occupancy sensors, etc. for controlling a variable speed compressor, evaporator fan and condenser fan. A fuel fired heater is positioned between an evaporator coil in the inlet of an enclosure and the evaporator fan in an outlet of the enclosure such that air flow passes around the heater. The power electronics to operate the system may be actively cooled by connection tubing providing a heat sink between an evaporator outlet and a compressor inlet.

Abstract: A method, non-transitory computer readable medium, and pharmaceutical assessment computing device that effectively reformulates and repositions pharmaceutical molecule data. With this technology, therapeutic area data comprising a medical condition and pharmaceutical molecule data corresponding to the medical condition is obtained. The pharmaceutical molecule data comprises pharmaceutical molecule identifiers and usage data parameters with corresponding usage data values for each of the pharmaceutical molecule identifiers. Each of the usage data values is compared to a corresponding usage threshold value. Reformulation opportunities are determined for each of the pharmaceutical molecule identifiers comprising a usage data value that exceeds the corresponding usage threshold value.